Structure- and fragment-based approaches to protease inhibition

Current Topics in Medicinal Chemistry

Volumn 6, Issue 4, 2006, Pages 317-329

  Johnson, Sherida L ^a   Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Benzodioxane derivative (BI 7E7); Cathepsin inhibitors; Computational docking methods; Cysteine proteases; Matrix metallo protease inhibitors; NMR based screening

Indexed keywords

ASPARTIC PROTEINASE; BI 7E7; BOTULINUM TOXIN; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 7; CASPASE 8; CASPASE INHIBITOR; CATHEPSIN B; CATHEPSIN L; CP 271485; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DIOXANE DERIVATIVE; FALCIPAIN 2; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; PD 0359601; PF 00356231; PROTEINASE; PROTEINASE INHIBITOR; RUPINTRIVIR; SERINE PROTEINASE; STROMELYSIN INHIBITOR; TETANUS TOXIN; THREONINE PROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZLIII 115A; ZLIII 43A;

ALLERGIC REACTION; BLOOD CLOTTING; BONE REMODELING; CELL DEATH; CELL GROWTH; COMPUTER ANALYSIS; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; FERTILIZATION; GENE TARGETING; HIGH THROUGHPUT SCREENING; INFECTION; INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PROTEIN STRUCTURE; PROTEINASE INHIBITION; REGULATORY MECHANISM; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; STRUCTURE ANALYSIS; TUMOR GROWTH; X RAY CRYSTALLOGRAPHY;

ANIMALS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS;

EID: 33646161254     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776287072     Document Type: Review

References (84)

1. Abbenante, G.; Fairlie, D. P. Protease inhibitors in the clinic. Med. Chem. 2005, 1, 71-104.
2. Rzychon, M.; Chmiel, D.; Stec-Niemczyk, J. Modes of inhibition of cysteine proteases. Acta Biochim. Pol. 2004, 51, 861-873
3. Barrett, A. J.; Rawlings, N. D.; Woessner, J. F., Handbook of Proteolytic Enzymes. Academic Press: San Diego, CA, 1998.
4. Thornberry, N. A.; Bull, H. G.; Calaycay, J. R.; Chapman, K. T.; Howard, A. D.; Kostura, M. J.; Miller, D. K.; Molineaux, S. M.; Weidner, J. R.; Aunins, J. A novel beterodimeric cysteine protease is required for interleukin-lβ processing in monocytes. Nature 1992, 356, 768-774.
5. Schneider, G.; Bohm, H. Virtual screening and fast automated docking methods. Drug Discov. Today 2002, 7, 64-70.
6. Bailey, D.; Brown, D. Higb-throughput chemistry and structure-based design: survival of the smartest. Drug Discov. Today 2001, 6, 57-59.
7. Bohm, H.-J.; Schneider, G., Virtual screening for bioactive molecules. Wiley-VCH Weinheim 2000; Vol. 10.
8. McMartin, C.; Bohacek, R. S. QXP: powerful, rapid computer algorithms for structure-based design. J. Comput. -Aided Mol. Des. 1997, 11, 333-344.
9. Schnecke, V.; Swanson, C. A.; Getzoff, E. D.; Tainer, J. A.; Kuhn, L. A. Screening a peptidyl database for potential ligands to proteins with side-chain flexibility. Proteins 1998, 33, 74-87.
10. Claussen, H.; Buning, C.; Rarey, M.; Lengauer, T., Molecular docking into the flexible active site of aldosereductase using FlexE. In Rational Approaches to Drug Design: Proceedings of 13th European Symposium on Quantitative Structure Activity Relationships, Holtje, H.; Sippl, W., Eds. Prous Science: Barcelona, 2001; pp. 324-333.
11. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M:; Tickle, I. J; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48, 403-413.
12. Blundell, T. L.; Abell, C.; Cleasby, A.; Hartshorn, M. J.; Tickle, I. J.; Parasini, E.; Jhoti, H., High-throughput X-ray crystallography for drug discovery. In Drug design: special publication, Flower, D. R., Ed. Royal Society of Chemistry: Cambridge, 2002; pp 53-59.
13. Shariff, A. J. High-throughput crystallography on an in-house source using ACTOR. Rigaku J. 2004, 20, 5-10.
14. Pellecchia, M.; Becattini, B.; Crowell, K. J.; Fattorusso, R.; Forino, M.; GRajai, M.; Jung, D.; Mustelin, T.; Tautz, L. NMR-based techniques in the hit identification and optimisation processes. Ex. Op. Ther. Tar. 2004, 8, 1-15.
15. Dalvit, C.; Ardini, E.; Flocco, M.; Fogliatto, G. P.; Mongelli, N.; Veronesi, M. A general NMR method for rapid, efficient, and reliable biochemical screening. J. Am. Chem. Soc. 2003, 125, 14620-14625.
16. Meyer, B.; Peters, T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int.-Ed. Engl. 2003, 42, 864-890.
17. Fielding, L. NMR methods for the determination of protein-ligand dissociation constants. Curr. Top, Med. Chem. 2003, 3, 39-53.
18. Greig, J. T. Fluorine nuclear magnetic resonance of fluorinated ligands. Methods Enzymol. 1989, 177, 3-23.
19. Leung, D. A.., G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
20. Shaw, E. Cysteinyl proteinases and their selective inactivation. Adv. Enzymol. Relat. Areas Mol. Biol. 1990, 63, 271-347.
21. Gibson, W.; Hall, M. R. T., Assemblin, an essential herpesvirus proteinase. In Drug Design and Discovery, Flynn, D., Ed. Harwood Academic Publishers: Langhorn, 1997; Vol. 15, pp 39-47.
22. Bernstein, P. R.; Edwards, P. D.; Williams, J. C. Inhibitors of human leukocyte elastase. Prog. Med. Chem. 1994, 31, 59-120.
23. Lecaille, F.; Kaleta, J.; Bromme, D. Human and parasitic papain-like cysteine proteases: Their role in physiology and pathology and recent develpments in inhibitor design. Chem. Rev. 2002, 102, 4459-4488.
24. Otto, H. H.; Schirmeister, T. Cysteine protease and their inhibitors. Chem. Rev. 1997, 97, 133-172.
25. McGrath, M. E. The lysosomal cysteine proteases. Annu. Rev. Biophys. Biomol. Struct. 1999, 28, 181-204.
26. Chapman, H. A.; Riese, J. R.; Shi, G. P. Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol. 1997, 59, 63-88.
27. Choong, I. C.; Lew, W.; Lee, D.; Pham, P.; Burdett, M. T.; Lam, J. W.; Wiesman, C.; Luong, T. N.; Fahr, B.; DeLano, W. L.; McDowell, R. S.; Allen, D. A.; Erlanson, D. A.; Gordon, E. M.; O'Brien, T. Identification of Potent and Selective Small-Molecule Inhibitors of Caspase -3 through the Used of Extended Tethering and Structure-Based Drug Design. J. Med. Chem. 2002, 45, 5005-5022.
28. Alnemri, E. S.; Livingston, D. J.; Nicholson, D. W.; Salvesen, G.; Thornberry, N. A.; Wong, W. W.; Yuan, J. Human ICE/CED-3 protease nomenclature. Cell 1996, 87, 171.
29. Fattorusso, R.; Jung, D.; Crowell, K. J.; Forino, M.; Pellecchia, M. Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach. J. Med. Chem. 2005, 48, 1649-1656.
30. Fuentes-Prior, P.; Salvesen, G. S. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 2004, 384, 201-232.
31. Cerretti, D. P.; Kozlosky, C. J.; Mosley, B.; Nelson, N.; Van Ness, K..; Greenstreet, T. A..; March, C. J.; Kronheim, S. R.; Druck, T.; Cannizzaro, L. A..; Huebner, K.; Black, R. A. Molecular cloning of the interleukin-1β converting enzyme. Science 1992, 256, 97-100.
32. Talanian, R. V.; Brady, K. D.; Cryns, V. L. Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery. J. Med. Chem. 2000, 43, 3351-3371.
33. Thornberry, N. A. Caspases: key mediators of apoptosis. Chem. Biol. 1998, 5, R97-R103.
34. Ator, M. A.; Dolle, R. E. Interleukin-1β Converting enzyme: biology and the chemistry of inhibitors. Curr. Pharm. Des. 1995, 1, 191-210.
35. McBride, C. B.; McPhail, L. T.; Steeves, J. D. Emerging Therapeutic Targets in Caspase-Dependent Disease. Emerging Ther. Targets 1999, 3, 391-411.
36. Lamer, A. J. Neuronal apoptosis as a therapeutic target in neurodegenerative disease. Ex. Op. Ther. Tar. 2000, 10, 1493-1518.
37. Verdonk, M. L.; Cole, J. C.; Harshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
38. Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graph. Model. 2002, 20, 281-295.
39. Rognan, D.; Lauemoller, S. L.; Holm, A.; Buus, S.; Tschinke, V. Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibililty proteins. J. Med. Chem. 1999, 42, 4650-4658.
40. Shahripour, A. B.; Plummer, M. S.; Lunney, E. A.; Albrecht, H. P.; Hays, S. J.; Kostlan, C. R.; Sawyer, T. K.; Walker, N. P. C.; Brady, K. D.; Allen, H. J.; Talanian, R. V.; Wong, W. W.; Humblet, C. Structure-based design of nonpeptide inhibitors of Interleukin-1β-converting enzyme (ICE, caspase-1). Bioorg. Med. Chem. 2002, 10, 31-40.
41. Desai, P. V.; Patny, A.; Sabnis, Y.; Tekwani, B.; Gut, J.; Rosenthal, P.; Srivastava, A.; Avery, M. Identification of Novel Parasitic Cysteine Protease Inhibitors Using Virtual Screening. 1. The ChemBridge Database. J. Med. Chem. 2004, 47, 6609-6615.
42. Selzer, P. M.; Pingel, S.; Hsieh, L; Ugele, B.; Chan, V. J.; Engel, J. C.; Bogyo, M.; Russell, D. G.; Sakanari, J. A.; McKerrow, J. H. Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target. Proc. Natl. Acad. Sci. USA 1999, 96, 11015-11022.
43. Selzer, P. M.; Chen, X.; Chan, V. J.; Cheng, M.; Kenyon, G. L.; Kuntz, I. D.; Sakanari, J. A.; Cohen, F. E.; McKerrow, J. H. Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp. Parasitol. 1997, 87, 212-221.
44. Ring, C. S.; Sun, E.; McKerrow, J. H.; Lee, G. K.; Rosenthal, P. J.; Kuntz, I. D.; Cohen, F. E. Structure-based inhibitor design by using protein models for the development of antiparasitc agents. Proc. Natl. Acad. Sci. USA 1993, 90, 3583-3587.
45. Li, R.; Chen, X.; Gong, B.; Selzer, P. M.; Li, Z.; Davidson, E.; Kurzban, G.; Miler, R. E.; Nuzum, E. O.; McKerrow, J. H.; Fletterick, R. J.; Gillmor, S. A.; Craik, C. S.; Kuntz, I. D.; Cohen, F. E.; Kenyon, G. L. Structure-based design of parasitic protease inhibitors. Bioorg. Med. Chem. 1996, 4, 1421-1427.
46. Thurmond, R. L.; Beavers, M. P.; Cai, H.; Meduna, S. P.; Gustin, D. J.; Sun, S.; Almond, H. J.; Karlsson, L.; Edwards, J. P. Nonpeptidic, Noncovalent Inhibitors of the Cysteine Protease Cathepsin S. J. Med. Chem. 2004, 47, 4799-4801.
47. Turk, B.; Turk, D.; Turk, V. Review: Lysosomal cysteine proteases: moree than scavengers. Biochim. Biophys. Acta 2000, 1477 (1-2), 98-111.
48. Buhling, F.; Fengler, A.; Brandt, W.; Welte, T.; Ansorge, S.; Nagler, D. K. Review: Novel cysteine proteases of the papain family. Adv. Exp. Med. Biol. 2000, 477, 241-254.
49. Rajnarayanan, R. V.; Dakshanamurthy, S.; Pattabiraman, N. "Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs. Biochem. Biophys. Res. Comm. 2004, 321, 370-378.
50. Puerta, D. T.; Cohen, S. M. A bioinorganic perspective on matrix metalloproteinase inhibition. Curr. Top. Med. Chem. 2004, 4, 1551-1573.
51. Ramos, O. H. P.; Selistre-de-Araujo, H. S. Identification of metalloprotease gen families in sugercane. Gen. Mol. Biol. 2001, 24, 285-290.
52. Stocker, W.; Bode, W. Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr. Op. Struct. Biol. 1995, 5, 383-390.
53. Martrisian, L. M. The matrix-degrading inetalloproteinases. Bioessays 1992, 14, 455-463.
54. Rossetto, O.; Montecucco, C., Bacterial toxins with metalloprotease activity. In Perspectives in Molecular Toxicology, Menez, A., Ed. John Wiley & Sons, Ltd: 2002; pp 1-21.
55. Rush III, T. S.; Powers, R. The application of X-ray, NMR and molecular modeling in the design of MMP inhibitors. Curr. Top. Med. Chem. 2004, 4, 1311-1327.
56. Levin, J. I. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. Curr. Top. Med. Chem. 2004, 4. 1289-1310.
57. Hidalgo, M.; Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. Hematol. Oncol. Clin. North. Am. 2001, 16, 1189-1227.
58. Hajduk, P. J.; Shuker, S. B.; Nettesheim, D. G.; Criag, R.; Augeri, D. J.; Betebenner, D.; Albert, D. H.; Goo, Y.; Meadows, R. P.; Xu, L.; Michaelidies, M.; Davidsen, S. K.; Fesik, S. W. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J. Med. Chem. 2002, 45, 5628-5639.
59. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.; Carrera, J., G. M.; Marcotte, P. A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 1997, 119, 5818-5827.
60. 15N chemical shift differences in MMP-3 ligands. Bioorg. Med. Chem. Lett. 2005,15,1779-1783.
61. Bodenhausen, G.; Ruben, D. J. Natural abundance nitrogen-15 NMR by enhanced heteronuclear spectroscopy Chem. Phys. Lett. 1980, 69,185-189.
62. Kay, L.; Keifer, P.; Saarinen, T. Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. J. Am. Chem. Soc. 1992, 114, 10663-10665.
63. Zhang, Y.; Xu, J.; Levin, J.; Hegen, M.; Li, G.; Rovbertshaw, H.; Brenan, F.; Cummons, T.; Clarke, D.; Vansell, N.; Nickerson-Nutter, C.; Barone, D.; Mohler, K.; Black, R.; Skotnicki, J.; Gibbons, J.; Feldmann, M.; Frost, P.; Larsen, G.; Lin, L. Identification and characterization of 4- 4-(2-butynyloxy) phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thio m-orpholincarboxamide (TIMI), a novel dual tumor necrosis factor-α-converting enzyme/matrix metaloprotease inhibitor for the treatment of rheumatoid arthritis. J. Pharm. Exp. Ther. 2004, 309, 348-355.
64. Morales, R.; Perrier, S.; Florent, J.-M.; Beltra, J.; Dufour, S.; Mendez, I. D.; Manceau, P.; Tertre, A.; Moreau, F.; Compere, D.; Dublanchet, A.-C.; O'Gara, M. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J. Mol. Biol. 2004, 341, 1063-1076.
65. Forino, M.; Johnson, S.; Wong, T. Y.; Rozanov, D. V.; Savinov, A. Y.; Li, W.; Fattorusso, R.; Becattini, B.; Orry, A. J.; Abagyan, R. A.; Smith, J. W.; Alibek K.; Liddington, R. C.; Strongin, A. Y.; Pellecchia, M. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. USA 2005, 102, 9499-9504
66. Johnson, S.; Jung, D.; Forino, M.; Chen, Y.; Satterthwait, A.; Rozanov, D. V.; Strongin, A. Y.; Pellecchia, M. Anthrax lethal factor protease inhibitors: synthesis, SAR and structure-based 3D QSAR studies. J. Med Chem. (letter) 2005, in press.
67. Shapiro, R. L.; Hatheway, C.; Swerdlow, D. L, Botulism in the United States: A Clinical and Epidemiologic Review. Ann. Intern. Med. 1998,129, 221-228.
68. Park, J. G.; Sill, P. C.; Makiyi, E. F.; Garcia-Sosa, A. T.; Millard, C. B.; Schmidt, J. J.; Ping, Y. Serotype-selective, small molecule inhibitors of the zinc endopeptidase of boutlinium neurotoxin serotype A. Bioorg. Med. Chem. 2006, 14, 395-408.
69. Pang, Y.-P. Novel zinc protein molecular dynamics silmulations: steps toward antiangiogenesis for cancer treatment. J. Mol. Model. 1999, 5, 196-202.
70. Pang, Y.-P.; Xu, K.; El Yazal, J.; Prendergast, F. G. Successful molecular dynamics simulation of the zinc-bound farnesyltransferase using the cationic dummy atom approach. Protein Sci. 2000, 9, 1857-1865.
71. Pang, Y.-P. Successful molecular dynamics simulation of two zinc complexes bridged by a hydroxide in phosphotriesterase using the cationic dummy atom method. Proteins 2001, 45,183-189.
72. Oelschlaeger, P.; Schmid, R. D.; Pleiss, J. Insight into the mechanism of the IMP-1 metallo-B-lactamase by molecular dynamics simulations. Protein Eng. 2003,16, 341-350.
73. Oelschlaeger, P.; Schmid, R. D.; Pleiss, J. Modeling Domino Effects in Enzymes: Molecular Basis of the Substrate Specificity of the Bacterial Metallo-β-lactamases IMP-1 and IMP-6. Biochemistry 2003, 42, 8945-8956.
74. Hoops, S. C.; Anderson, K. W.; Merz, K. M. Force field design for metalloproteins. J. Am. Chem. Soc. 1991, 113, 8262-8270.
75. Ryde, U. Molecular dynamics simulations of alcohol dehydrogenase with a four- or five-coordinate catalytic zinc ion. Proteins 1995, 21, 40-56.
76. Lu, D. S.; Voth, G. A. Molecular dynamics simulations of human carbonic anhydrase II: Insight into experimental results and the role of solvation. Proteins 1998, 33, 119-134.
77. Berweger, C. D.; Thiel, W.; Van Gunsteren, W. F. Molecular-dynamics simulation of the β domain of metallothionein with a semi-empirical treatment of the metal core. Proteins 2000, 41, 299-315.
78. Breidenbach, M. A.; Brunger, A. T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432, 925-929.
79. Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G.; Pang, Y.-P. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. J. Med. Chem. 2000, 43, 401-408.
80. Lightstone, F. C.; Prieto, M. C.; Singh, A. K.; Piqueras, M. C.; Whittal, R. M.; Knapp, M. S.; Balhom, R.; Roe, D. C. Identification of novel small molecule ligands that bind to Tetanus toxin. Chem. Res. ToxicoL 2000, 13, 356-362.
81. Rogers, T. B.; Snyder, S. H. High affinity binding of tetanus toxin to mammalian brain membranes. J. Biol. Chem. 1981, 256, 2402-2407.
82. Morris, N. P.; Cosniglio, E.; Kohn, L. D.; Habig, W. H.; Hardegree, M. C.; Helting, T. B. Interaction of fragments B and C of tetanus toxin with neural and thyroid membranes and with gangliosides. J. Biol. Chem. 1980, 255, 6071-6076.
83. Holmgren, J.; Elwing, H.; Fredman, P.; Svennerholm, L. Polystyrene-adsorbed gangliosides for investigation of the structure of the tetanus-toxin receptor. Eur. J. Blochem. 1980, 106, 371-379.
84. Winter, A.; Ulrich, W. P.; Wetterich, F.; Weller, U.; Galla, H. J. Gangliosides-bilayer membranes: Interaction with tetanus toxin. Chem. Phys. Lipids 1996, 81, 21-34.